Vivos Therapeutics’ (VVOS) Buy Rating Reiterated at Ascendiant Capital Markets

Ascendiant Capital Markets reaffirmed their buy rating on shares of Vivos Therapeutics (NASDAQ:VVOS) in a research note published on Wednesday morning,Benzinga reports. They currently have a $6.60 price objective on the stock.

Separately, Alliance Global Partners lowered their price objective on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th.

Vivos Therapeutics Price Performance

NASDAQ VVOS opened at $3.20 on Wednesday. The business’s fifty day moving average is $2.79 and its 200-day moving average is $2.53. The stock has a market capitalization of $15.47 million, a price-to-earnings ratio of -0.56 and a beta of 7.71. Vivos Therapeutics has a one year low of $1.91 and a one year high of $48.79.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.